India's Sun Pharma gets FDA nod for four generics
India-based Sun Pharmaceutical Industries Ltd has made announcement that the company along with its arm, has got first U.S. Food and Drug Administration sanction to market the generic version of a controlled substance in tablet form.
According to sources, the company is allowed to sell generic hydrocodone bitartate with acetaminophen in multiple strengths, which has a U.S. market size of $540 million for branded and generic versions.
Sun also secured approval for generic versions of cholesterol-fighting Lopid, Aredia, indicated in the treatment of high blood calcium, and anti-allergent Phenargen in multiple strengths.
January 09, 2009